Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1800 participants
OBSERVATIONAL
2020-02-21
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to assess the delay between the first appointment with the oncologist and the beginning of the antitumoral treatment, and therefore evaluate the efficacy of the care pathway unit.
The second aim is to assess the satisfaction of patients and health care teams.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patient Empowerment and Risk-assessed Treatment to Improve Outcome in the Elderly After Onco-surgery
NCT01278537
Feasibility Study of a Transition Pathway at Discharge From Full Hospitalization in Oncology
NCT07256444
Onco-coaching of Sport-inspired for the Social, Professional and Psychological Restoring of the Patients in Cancer Remission After Allogeneic Transplantation of Hematopoietic Stem Cells
NCT03272789
A Patient Consensus for the Research in Supportive Care in French Cancer Care Centers: the CyPRES Project
NCT03320161
Evaluation of a Oncology Day Care Unit Programme With Two Different Focuses
NCT04411251
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For the retrospective cohort, patient will be selected through the use of data warehouse available on the HEGP.
For the prospective cohort, patient will be included according to the selection criteria.
Each patient will be followed up during 6 month and a satisfaction questionnaire will be completed at 1 month and 4 month of the first administration of anti-tumor therapy.
For both cohort, clinical-anatomo-biological data will be collected through the use of data warehouse available on the HEGP.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Historic cohort
Retrospective cohort of patients that were treated in the Hôpital Européen Georges Pompidou before the creation of the care pathway unit.
No interventions assigned to this group
Prospective cohort
All consecutive patients that meet the inclusion criterion and will begin a cancer care after the study start.
Care pathway unit
Patients from the prospective cohort will have their health care scheduled by the care pathway unit.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Care pathway unit
Patients from the prospective cohort will have their health care scheduled by the care pathway unit.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* First appointment for cancer care at the Hôpital Européen Georges Pompidou
* Intravenous antitumoral treatment
Exclusion Criteria
* Radiochemotherapy
* Death in the 6 months following first oncological appointment or absence of medical care in the year following the first oncological appointment
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MSD France
INDUSTRY
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Virginie Bichon
Role: PRINCIPAL_INVESTIGATOR
AP-HP, Hôpital Européen Georges Pompidou, Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AP-HP Hôpital européen Georges-Pompidou
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP190973
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.